{"nctId":"NCT00049842","briefTitle":"Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)","startDateStruct":{"date":"2002-10"},"conditions":["Chronic Hepatitis C","Liver Fibrosis"],"count":540,"armGroups":[{"label":"PEG-Intron (peginterferon alfa-2b) 0.5 Âµg/kg Weekly (QW)","type":"EXPERIMENTAL","interventionNames":["Biological: peginterferon alfa-2b (SCH 54031)"]},{"label":"Untreated Control","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"peginterferon alfa-2b (SCH 54031)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age at entry in study P02370 (NCT00039871) 18-65 years;\n* Nonresponder to PEG-Intron plus Rebetol in study P02370\n\nExclusion Criteria:\n\n* Participants who did not participate in the P02370 study.\n* Any medical condition, including but not limited to decompensated liver disease, malignancy or substance abuse, that developed during the P02370 study which could interfere with the participant's participation in and completion of this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Fibrosis Response Status (ie, Improvement, no Change, or the Worsening of the Fibrosis Score in Participants With Baseline METAVIR Fibrosis Score of F2 or F3).","description":"Definitions:\n\nFibrosis scoring: F0 (no fibrosis), F1 (stellate enlargement of portal tract without septa formation, F2 (enlargement of portal tract with rare septa formation, F3 (numerous septa without cirrhosis), F4 (cirrhosis).\n\nImproved: Participants whose METAVIR fibrosis score at up to Month-36 decreases by 1 or more units compared to baseline.\n\nNo Change: Participants whose METAVIR fibrosis score at up to Month-36 is the same as the baseline score.\n\nWorsened: Participants whose METAVIR fibrosis score at up to Month-36 increases by 1 or more units compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"162","spread":null},{"groupId":"OG001","value":"176","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Inflammation Response Status (ie, Improvement, no Change, or the Worsening of the METAVIR Activity Score as Compared to Baseline)","description":"Activity Scoring: A0 (no histological activity), A1 (minimal activity), A2 (moderate activity), A3 (severe activity), A4 (lobular chronic hepatitis).\n\nChanges in liver inflammation defined as follows:\n\nImproved: Participants whose METAVIR activity score at up to Month-36 decreases by 1 or more units compared to baseline.\n\nNo Change: Participants whose METAVIR activity score at up to Month-36 is the same as the baseline score.\n\nWorsened: Participants whose METAVIR activity score at up to Month-36 increases by 1 or more units compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"195","spread":null},{"groupId":"OG001","value":"209","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to up to Month-36 in the METAVIR Fibrosis Score (Using a Continuous Scale)","description":"The change of Metavir Fibrosis Score = Metavir Fibrosis Score at up to Month-36 - Metavir Fibrosis Score at Baseline.\n\nFibrosis scoring: 0 (no fibrosis), 1 (stellate enlargement of portal tract without septa formation, 2 (enlargement of portal tract with rare septa formation, 3 (numerous septa without cirrhosis), 4 (cirrhosis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.977"},{"groupId":"OG001","value":"0.31","spread":"1.002"}]}]}]},{"type":"SECONDARY","title":"The Number of Participants Whose METAVIR Fibrosis Score Did Not Worsen (ie, the Response Status of Improved/no Change) During Treatment Compared to Baseline","description":"Definitions:\n\nFibrosis scoring: F0 (no fibrosis), F1 (stellate enlargement of portal tract without septa formation, F2 (enlargement of portal tract with rare septa formation, F3 (numerous septa without cirrhosis), F4 (cirrhosis).\n\nImproved: Participants whose METAVIR fibrosis score at up to Month-36 decreases by 1 or more units compared to baseline.\n\nNo Change: Participants whose METAVIR fibrosis score at up to Month-36 is the same as the baseline score.\n\nWorsened: Participants whose METAVIR fibrosis score at up to Month-36 increases by 1 or more units compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"206","spread":null},{"groupId":"OG001","value":"205","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in the METAVIR Activity Score (Using a Continuous Scale)","description":"The change of Metavir Activity Score = Metavir Activity Score at up to Month-36 - Metavir Activity Score at Baseline.\n\nActivity Scoring: 0 (no histological activity), 1 (minimal activity), 2 (moderate activity), 3 (severe activity), 4 (lobular chronic hepatitis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"0.709"},{"groupId":"OG001","value":"0.11","spread":"0.642"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With no Worsening (ie, the Response Status of Improved/ no Change) in the METAVIR Activity Score During the Treatment.","description":"Definitions:\n\nActivity Scoring: A0 (no histological activity), A1 (minimal activity), A2 (moderate activity), A3 (severe activity), A4 (lobular chronic hepatitis).\n\nImproved: Participants whose METAVIR activity score at up to Month-36 decreases by 1 or more units compared to baseline.\n\nNo Change: Participants whose METAVIR activity score at up to Month-36 is the same as the baseline score.\n\nWorsened: Participants whose METAVIR activity score at up to Month-36 increases by 1 or more units compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"249","spread":null},{"groupId":"OG001","value":"232","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":53,"n":270},"commonTop":["FATIGUE","INSOMNIA","HEADACHE","ARTHRALGIA","ASTHENIA"]}}}